Mostrar el registro sencillo del ítem

resumen

Resumen
SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including [ver mas...]
dc.contributor.authorCastro, Eliana Florencia
dc.contributor.authorAcosta, Julián
dc.contributor.authorMoriena, Lucía
dc.contributor.authorRios Medrano, Mayra
dc.contributor.authorCibello, Malena Tejerina
dc.contributor.authorCodino, Eduardo
dc.contributor.authorTaborda, Miguel Ángel
dc.contributor.authorÁlvarez, Diego E.
dc.contributor.authorCavatorta, Ana
dc.date.accessioned2024-02-14T16:56:51Z
dc.date.available2024-02-14T16:56:51Z
dc.date.issued2023-06
dc.identifier.issn2379-5042
dc.identifier.otherhttps://doi.org/10.1128/msphere.00662-22
dc.identifier.urihttp://hdl.handle.net/20.500.12123/16603
dc.identifier.urihttps://journals.asm.org/doi/10.1128/msphere.00662-22
dc.description.abstractSARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels.eng
dc.formatapplication/pdfes_AR
dc.language.isoenges_AR
dc.publisherAmerican Society for Microbiologyes_AR
dc.rightsinfo:eu-repo/semantics/openAccesses_AR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/es_AR
dc.sourcemSphere 8 (3) : e0066222 (June 2023)es_AR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2eng
dc.subjectCoronavirus del Síndrome Respiratorio Agudo Grave 2es_AR
dc.subjectHumoral Immunityeng
dc.subjectInmunidad Humorales_AR
dc.subjectImmune Responseeng
dc.subjectRespuesta Inmunológicaes_AR
dc.subjectVaccinationeng
dc.subjectVacunaciónes_AR
dc.subjectArgentinaes_AR
dc.subject.otherSputnik Ves_AR
dc.titleLongitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccinationes_AR
dc.typeinfo:ar-repo/semantics/artículoes_AR
dc.typeinfo:eu-repo/semantics/articlees_AR
dc.typeinfo:eu-repo/semantics/publishedVersiones_AR
dc.rights.licenseCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)es_AR
dc.description.origenInstituto de Virologíaes_AR
dc.description.filFil: Castro, Eliana Florencia. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentinaes_AR
dc.description.filFil: Castro, Eliana Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentinaes_AR
dc.description.filFil: Castro, Eliana Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentinaes_AR
dc.description.filFil: Acosta, Julián. Instituto de Biología Molecular y Celular de Rosario; Argentinaes_AR
dc.description.filFil: Acosta, Julián. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentinaes_AR
dc.description.filFil: Acosta, Julián. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentinaes_AR
dc.description.filFil: Moriena, Lucía. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública (CTSP); Argentinaes_AR
dc.description.filFil: Rios Medrano, Mayra. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentinaes_AR
dc.description.filFil: Rios Medrano, Mayra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentines_AR
dc.description.filFil: Cibello, Malena Tejerina. Universidad Nacional de San Martín. Escuela de Bio y Nanotecnologías; Argentinaes_AR
dc.description.filFil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentinaes_AR
dc.description.filFil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública; Argentinaes_AR
dc.description.filFil: Taborda, Miguel Ángel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentinaes_AR
dc.description.filFil: Álvarez, Diego E. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentinaes_AR
dc.description.filFil: Álvarez, Diego E. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentinaes_AR
dc.description.filFil: Cavatorta, Ana. Instituto de Biología Molecular y Celular de Rosario; Argentinaes_AR
dc.description.filFil: Cavatorta, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentinaes_AR
dc.description.filFil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentinaes_AR
dc.description.filFil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología En Salud Pública; Argentinaes_AR
dc.subtypecientifico


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

common

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/openAccess
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/openAccess